Drug intelligence / Profile preview

CLF065

Development stage: Unknown
Lead developer: Scripps Research
Modality: Peptides
Administration: Subcutaneous

Overview

CLF065 is a long-acting, fatty acid-stapled glucagon-like peptide-2 (GLP-2) analog developed by Calibr, a division of Scripps Research. It is designed to promote intestinal barrier regeneration and mucosal healing by acting as a potent agonist of the GLP-2 receptor. The drug's unique stapled peptide structure extends its half-life, allowing for a weekly subcutaneous dosing regimen. CLF065 is primarily being investigated for the treatment of chronic pouchitis, a condition characterized by inflammation of the ileal pouch following colorectal surgery, as well as other forms of inflammatory bowel disease (IBD).

Targets

GLP2R (Glucagon-like peptide 2 receptor)

Beyond the preview

Go deeper on CLF065.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLF065.

Explore the full profile